126 related articles for article (PubMed ID: 38903511)
1. Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections.
Sejdic A; Hartling HJ; Holler JG; Klingen Gjærde L; Lindegaard B; Dungu AM; Gnesin F; Møller MEE; Teglgaard RS; Niemann CU; Brooks PT; Jørgensen CS; Franck KT; Fischer TK; Marquart HV; Harboe ZB; Ostrowski SR
Front Immunol; 2024; 15():1360843. PubMed ID: 38903511
[TBL] [Abstract][Full Text] [Related]
2. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Datwani S; Kalikawe R; Waterworth R; Mwimanzi FM; Liang R; Sang Y; Lapointe HR; Cheung PK; Omondi FH; Duncan MC; Barad E; Speckmaier S; Moran-Garcia N; DeMarco ML; Hedgcock M; Costiniuk CT; Hull M; Harris M; Romney MG; Montaner JSG; Brumme ZL; Brockman MA
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793543
[TBL] [Abstract][Full Text] [Related]
3. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
Front Immunol; 2021; 12():742914. PubMed ID: 34659237
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
5. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon.
Nour D; Ismail MB; Osman M; Rafei R; Kasir D; Dabboussi F; Colson P; Hamze M
PLoS One; 2024; 19(5):e0302579. PubMed ID: 38722969
[TBL] [Abstract][Full Text] [Related]
7. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM
Front Immunol; 2024; 15():1372193. PubMed ID: 38812507
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults.
Prelog M; Jeske SD; Asam C; Fuchs A; Wieser A; Gall C; Wytopil M; Mueller-Schmucker SM; Beileke S; Goekkaya M; Kling E; Geldmacher C; Rubio-Acero R; Plank M; Christa C; Willmann A; Vu M; Einhauser S; Weps M; Lampl BMJ; Almanzar G; Kousha K; Schwägerl V; Liebl B; Weber B; Drescher J; Scheidt J; Gefeller O; Messmann H; Protzer U; Liese J; Hoelscher M; Wagner R; Überla K; Steininger P;
J Clin Virol; 2024 Feb; 170():105622. PubMed ID: 38091664
[TBL] [Abstract][Full Text] [Related]
9. Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.
Almanzar G; Koosha K; Vogt T; Stein A; Ziegler L; Asam C; Weps M; Schwägerl V; Richter L; Hepp N; Fuchs A; Wagenhäuser I; Reusch J; Krone M; Geldmacher C; Protzer U; Steininger P; Überla K; Wagner R; Liese J; Prelog M
J Med Virol; 2024 Jun; 96(6):e29739. PubMed ID: 38899449
[TBL] [Abstract][Full Text] [Related]
10. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
11. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
13. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
[TBL] [Abstract][Full Text] [Related]
15. High interleukin-6 levels induced by COVID-19 pneumonia correlate with increased circulating follicular helper T cell frequency and strong neutralization antibody response in the acute phase of Omicron breakthrough infection.
Kawasuji H; Morinaga Y; Nagaoka K; Tani H; Yoshida Y; Yamada H; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Niimi H; Yamamoto Y
Front Immunol; 2024; 15():1377014. PubMed ID: 38694512
[TBL] [Abstract][Full Text] [Related]
16. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination.
Paniskaki K; Anft M; Meister TL; Marheinecke C; Pfaender S; Skrzypczyk S; Seibert FS; Thieme CJ; Konik MJ; Dolff S; Anastasiou O; Holzer B; Dittmer U; Queren C; Fricke L; Rohn H; Westhoff TH; Witzke O; Stervbo U; Roch T; Babel N
Front Immunol; 2022; 13():816220. PubMed ID: 35145522
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 breakthrough infections in rheumatic diseases patients after vaccination.
Alshukairi AN; Al-Omari A; Albeity A; Alandijany TA; Hassan AM; El-Kafrawy SA; Dada A; Al Hroub MK; El-Saed A; Bissar LS; Daghmush RM; Al-Ghamdi SMG; Perlman S; Azhar EI; Halabi H
J Infect Public Health; 2022 Jun; 15(6):685-688. PubMed ID: 35623243
[TBL] [Abstract][Full Text] [Related]
18. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
[TBL] [Abstract][Full Text] [Related]
19. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.
Servellita V; Morris MK; Sotomayor-Gonzalez A; Gliwa AS; Torres E; Brazer N; Zhou A; Hernandez KT; Sankaran M; Wang B; Wong D; Wang C; Zhang Y; Reyes KR; Glasner D; Deng X; Streithorst J; Miller S; Frias E; Rodgers M; Cloherty G; Hackett J; Hanson C; Wadford D; Philip S; Topper S; Sachdev D; Chiu CY
Nat Microbiol; 2022 Feb; 7(2):277-288. PubMed ID: 35013591
[TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]